
MULTIPLE MYELOMA AND ME

Mike Sheahan





MULTIPLE MYELOMA

- **Multiple myeloma** is a cancer of plasma cells (a type of white blood cell) that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone damage (lytic lesions), anemia, renal insufficiency, and infections may occur.
- The disease is treatable, but incurable.
- Globally, about 175,000 people were diagnosed with the disease in 2020, while about 117,000 people died from the disease that year.
- Based on data from people diagnosed with the disease in the United States between 2015 and 2021, about 62% lived five years or more post-diagnosis.
- My diagnosis summary: Standard blood labs from annual physical showed an elevated gamma fraction, which led to SPEP panel on 3/12/20, **IgA was 3,870mg/dL**, IgG only 422mg/dL, IgM down to 8mg/dL. Kappa light chain 21.7.
- My disease information: **IgA Kappa Myeloma**; R-ISS II, high risk due to cytogenetics and TP53 deletion.



TIMELINE

- March 23, 2020 – Diagnosis date (**IgA – 3,870**, Normal Range is 69-309 mg/dl)
- April 3, 2020 – Began first cycle of chemotherapy (the first of 5 cycles),
- August 25, 2020 – My birthday, crashed bicycle dislocating left knee (**IgA – 329**),
- September 1, 2020 – Stem cells are collected for a Stem Cell Transplant,
- September 30, 2020 – Surgical repair of the left knee (**IgA – 578**), off chemo, relapse,
- October 20, 2020 – **IgA – 987**,
- November 2020 – Enrolled in CAR-T clinical trial for relapsed Multiple Myeloma,
- January 11, 2021 – **IgA - 4,097**,
- January 22, 2021 - CAR T-cells (bb2121) infused as part of clinical trial,
- February 17, 2021 – **IgA – 346**
- Currently – bb2121 is a commercialized immunotherapy and is branded as ABECMA, clinical trial ended, **IgA – 261**, (Normal Range is 69-309 mg/dl)

MY COMMUNITY OF CARE

